Lymphoid markers as predictors of adult acute myeloid leukemia prognosis

Abstract

Background Acute myeloid leukaemia (AML) constitutes the most prevalent aggressive leukaemia in adults, with uncontrolled proliferation of immature myeloid cells and a variety of clinical manifestations. Whereas most AML patients respond to chemotherapy initially, half of all patients relapse within 5 years of being diagnosed. Aim and objectives The present study aimed to investigate the prognostic value of co expression of lymphocytes markers in patients with acute myeloid leukemia as regarding clinical outcome and survival. Patients and methods The present study was enrolled at Hematology Unit at Nasser Institute Hospital. This is a retrospective study done on (50) patients aged from 18 to 65 years, completion of treatment (or part of treatment undertaken), and follow-up duration of at least six months after diagnosis. Results The present study results showed a statistically significant difference between patients who achieved complete remission and those who relapsed or were refractory to treatment in the lymphoid markers CD7 and CD19. CD7 was the most frequent lymphoid marker. The lymphoid marker CD4 was associated with a higher complete remission rate. CD19 was associated with the highest relapse rate. Conclusion CD7 was the most frequent lymphoid marker. The lymphoid marker CD4 was associated with a higher complete remission rate compared to CD7, CD5, CD2 and CD19; While CD19 was associated with the highest relapse rate